Suominen Oyj:n puolivuosikatsaus 1.1.-30.6.2026: Liikevaihto ja vertailukelpoinen käyttökate paranivat toisella vuosineljänneksellä

Suominen reported Q2 2026 revenue of €105.6M (+5.8% YoY) and a rise in comparable EBITDA to €4.3M (€3.2M in Q2 2025). However, operating cash flow remained negative at -€4.5M (vs -€10.1M), and gearing improved to 51.6% from 85.5% following an upsized rights issue that raised ~€28M gross in early July. For 2026, the company expects comparable EBITDA to improve vs 2025 (€12.6M), supported by its Full Potential program targeting a 10% EBITDA margin.

Analysis

The balance-sheet reset matters more than the reported operating uptick. For a low-margin, working-capital-heavy nonwovens producer, the rights issue reduces near-term solvency risk and should lower equity risk premia, but it also means the market will likely demand proof that cash generation is structurally fixed before awarding any meaningful multiple rerating.

The important second-order signal is pricing discipline: moving to more frequent repricing is usually defensive evidence that the company still has pass-through power, but it also reveals the business is fighting a cost-inflation lag rather than enjoying true demand-led pricing. That creates a narrow window where margins can expand if input costs stabilize; if energy or polymer costs re-accelerate, the lag will hit again and any EBITDA recovery can flatten quickly. The Alicante ramp is the near-term execution catalyst: if approval drags further, the market will likely conclude that the improvement program is more narrative than P&L.

Contrarian view: the consensus may be underestimating dilution optics and overestimating the pace of recovery. A 10% EBITDA margin target is a multi-year aspiration from a low-single-digit base, so 2026 guidance improvement alone is not enough to justify aggressive optimism unless operating cash flow turns durably positive. The key falsifier is another quarter of weak cash conversion despite better EBITDA; that would imply the business is still dependent on balance-sheet repair rather than self-funded growth.

Key Decisions for Investors

• Watchlist only, not an immediate long: wait for the next quarter to confirm that EBITDA gains are converting into positive operating cash flow; if cash flow remains near zero or negative, do not chase the stock on the rights-issue de-risking.
• Tactical long only on post-event weakness if the market gives back the financing relief trade; use a 1-3 month horizon and require confirmation that the Alicante line is approved and contributing before adding size.
• Set a thesis alert on margin execution: if quarterly adjusted EBITDA does not move meaningfully above the recent run-rate by Q3, treat the recovery as delayed and reduce exposure.
• Contrarian short setup for a rally extension: fade any move that prices in the full 10% EBITDA target within 12 months; the better entry is after an approval/ramp headline if the market has already discounted a cleaner balance sheet.